- Home
- ADAP vs ATAI Comparison
ADAP vs ATAI Comparison
Compare ADAP & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- ATAI
- Stock Information
- Founded
- ADAP 2008
- ATAI 2018
- Country
- ADAP United Kingdom
- ATAI Germany
- Employees
- ADAP N/A
- ATAI N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- ATAI Health Care
- Exchange
- ADAP Nasdaq
- ATAI Nasdaq
- Market Cap
- ADAP 212.3M
- ATAI 214.8M
- IPO Year
- ADAP 2015
- ATAI 2021
- Fundamental
- Price
- ADAP $0.59
- ATAI $1.61
- Analyst Decision
- ADAP Strong Buy
- ATAI Strong Buy
- Analyst Count
- ADAP 4
- ATAI 3
- Target Price
- ADAP $3.16
- ATAI $10.50
- AVG Volume (30 Days)
- ADAP 2.0M
- ATAI 1.7M
- Earning Date
- ADAP 11-13-2024
- ATAI 11-13-2024
- Dividend Yield
- ADAP N/A
- ATAI N/A
- EPS Growth
- ADAP N/A
- ATAI N/A
- EPS
- ADAP N/A
- ATAI N/A
- Revenue
- ADAP $175,041,000.00
- ATAI $331,000.00
- Revenue This Year
- ADAP $180.15
- ATAI $44.72
- Revenue Next Year
- ADAP N/A
- ATAI N/A
- P/E Ratio
- ADAP N/A
- ATAI N/A
- Revenue Growth
- ADAP 146.27
- ATAI N/A
- 52 Week Low
- ADAP $0.42
- ATAI $1.03
- 52 Week High
- ADAP $2.05
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- ADAP 26.22
- ATAI 66.74
- Support Level
- ADAP $0.75
- ATAI $1.25
- Resistance Level
- ADAP $0.83
- ATAI $1.65
- Average True Range (ATR)
- ADAP 0.07
- ATAI 0.15
- MACD
- ADAP -0.01
- ATAI 0.04
- Stochastic Oscillator
- ADAP 2.36
- ATAI 93.29
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.